Desjardins Global Asset Management Inc. Boosts Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Desjardins Global Asset Management Inc. grew its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 15.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,074 shares of the medical device company’s stock after purchasing an additional 282 shares during the quarter. Desjardins Global Asset Management Inc.’s holdings in DexCom were worth $257,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. KB Financial Partners LLC purchased a new position in shares of DexCom during the 1st quarter valued at approximately $72,000. Bartlett & CO. Wealth Management LLC purchased a new position in shares of DexCom during the 4th quarter valued at approximately $27,000. Valley National Advisers Inc. increased its holdings in shares of DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. MV Capital Management Inc. increased its holdings in shares of DexCom by 99.3% during the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 138 shares in the last quarter. Finally, Harbour Investments Inc. increased its holdings in shares of DexCom by 55.6% during the 3rd quarter. Harbour Investments Inc. now owns 336 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 120 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Royal Bank of Canada assumed coverage on shares of DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price target on the stock. Citigroup lifted their price target on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. UBS Group lifted their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Raymond James lifted their price target on shares of DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a research note on Tuesday, January 23rd. Finally, StockNews.com raised shares of DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average target price of $141.40.

Insider Activity

In other news, CFO Jereme M. Sylvain sold 3,363 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total transaction of $392,562.99. Following the transaction, the chief financial officer now owns 71,142 shares of the company’s stock, valued at approximately $8,304,405.66. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, EVP Matthew Vincent Dolan sold 1,990 shares of the business’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the sale, the executive vice president now directly owns 42,377 shares in the company, valued at approximately $5,839,974.37. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Jereme M. Sylvain sold 3,363 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the sale, the chief financial officer now owns 71,142 shares in the company, valued at $8,304,405.66. The disclosure for this sale can be found here. In the last quarter, insiders have sold 189,375 shares of company stock valued at $25,530,859. 0.41% of the stock is currently owned by insiders.

DexCom Trading Up 0.3 %

Shares of DXCM stock opened at $134.30 on Friday. The company’s 50-day moving average price is $129.35 and its 200-day moving average price is $116.41. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. The stock has a market cap of $51.77 billion, a price-to-earnings ratio of 102.52, a PEG ratio of 2.35 and a beta of 1.20. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.07. The firm had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.02 billion. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The company’s revenue was up 26.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.34 EPS. As a group, equities analysts predict that DexCom, Inc. will post 1.76 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.